| INK Ultra Money Free |
Latest 10 SEC filings (by transaction date) for DBTX within the last 6 months | [?] |
![]() ![]() |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Feb 19/21 | Feb 19/21 | Exter Neil | Indirect Ownership | Common Stock | Form 3/A : Amendment of a previous Form 3 ![]() ![]() | ||
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Series D Preferred Stock | C - Conversion ![]() | -1,737,619 | |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Series C Preferred Stock | C - Conversion ![]() | -3,125,000 | |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Series A Preferred Stock | C - Conversion ![]() | -7,119,850 | |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Common Stock | P - Open market or private purchase ![]() | 150,000 | $18.00 |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Common Stock | C - Conversion ![]() | 327,852 | |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Common Stock | C - Conversion ![]() | 247,324 | |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Common Stock | C - Conversion ![]() | 458,487 | |
Feb 18/21 | Feb 17/21 | Longevity Fund 2 LP | Direct Ownership | Convertible Series C Preferred Stock | C - Conversion ![]() | -79,143 | |
Feb 18/21 | Feb 17/21 | Longevity Fund 2 LP | Direct Ownership | Common Stock | C - Conversion ![]() | 79,143 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for DBTX within the last 6 months | [?] |
![]() ![]() |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Series D Preferred Stock | C - Conversion ![]() | -1,737,619 | |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Series C Preferred Stock | C - Conversion ![]() | -3,125,000 | |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Series A Preferred Stock | C - Conversion ![]() | -7,119,850 | |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Common Stock | P - Open market or private purchase ![]() | 150,000 | $18.00 |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Common Stock | C - Conversion ![]() | 327,852 | |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Common Stock | C - Conversion ![]() | 247,324 | |
Feb 19/21 | Feb 17/21 | Glaxosmithkline Plc | Indirect Ownership | Common Stock | C - Conversion ![]() | 458,487 | |
Feb 19/21 | Feb 17/21 | Orbimed Advisors Llc | Indirect Ownership | Series D Preferred Stock | C - Conversion ![]() | -1,158,412 | |
Feb 19/21 | Feb 17/21 | Orbimed Advisors Llc | Indirect Ownership | Series D Preferred Stock | C - Conversion ![]() | -1,737,619 | |
Feb 19/21 | Feb 17/21 | Orbimed Advisors Llc | Indirect Ownership | Series D Preferred Stock | C - Conversion ![]() | -14,480,162 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Moderna (OQ:MRNA) |
Crispr Therapeutics AG (OQ:CRSP) |
Revolution Medicines (OQ:RVMD) |